芪丹益肾降糖丸对早期糖尿病肾病患者血清转化生长因子β1的影响_药学论文.docVIP

芪丹益肾降糖丸对早期糖尿病肾病患者血清转化生长因子β1的影响_药学论文 芪丹益肾降糖丸对早期糖尿病肾病患者血清转化生长因子β1的影响_药学论文 作者：李亚秋，贾凤新，宫彩霞，周凤伟，李倩，赵会娟，王占平 【摘要】 　　目的观察芪丹益肾降糖丸对早期糖尿病肾病患者血清转化生长因子β1(TGF的影响。方法选取糖尿病肾病早期患者61例，随机分为两组。对照组采用西药苯那普利常规治疗，治疗组在西药常规治疗基础上加服芪丹益肾降糖丸(院内制剂)治疗。对治疗前后相关数据进行比较。结果两组均能降低早期糖尿病肾病患者血清TGF水平（P＜0.01）；两组比较有显著性差异(P＜0.05)；治疗组治疗前后空腹血糖、糖化血红蛋白、尿微量白蛋白、肾功能、血脂、血清TGF等指标比较具有显著性差异（P＜0.05或P＜0.01）。结论芪丹益肾降糖丸联合常规西药治疗可显著降低早期糖尿病肾病血清TGF，疗效优于单用西药治疗。 【关键词】 糖尿病肾病 转化生长因子β1 芪丹益肾降糖丸 　　Abstract：ObjectiveTo study the effect of Qidanyishenjiangtang Pill on serum transforming growth factor-β1(TGF-β1) in patients with early diabetic nephropathy(EDN).MethodsSixty-one patients with EDN were randomly divided into the control group(n=30) and the treatment group(n=31). The control group was applied regular treatment of Benazepril and the treatment group was added to Qidanyishenjiangtang pill on the basis of regular treatment for 8 weeks. Serum TGF-β1 were determined with ELISA before and after treatment, and fasting blood glucose(FBG), HbAlc,urinary albumin excretion rate (UAER), serum creatinine(Scr), blood lipids were examed as well.ResultsCompared with pretreatment, the serum TGF-β1 level of both groups decreased significantly(P＜0.01) and the difference of two groups was obvious(P＜0.05). The difference between before and after treatment of the level of FBG,HbAlc,UAER,Scr,TC,TG,HDL-C,TGF-β1 were significant(P＜0.05 and P＜0.01).ConclusionQidanyishenjiangtang pill combined with Benazepril can markedly decreased the serum TGF-β1 level of EDN, the effect is better than Benazepril only. 　　Key words： Diabetic nephropathy; Transforming growth factor-β1; Qidanyishenjiangtang pill 　　糖尿病肾病(diabetic nephropathy，DN)是糖尿病常见而难治的慢性微血管并发症，弥漫性肾小球硬化是糖尿病的特异性肾损害，并已成为导致终末期肾功能衰竭最主要的病因之一，也是DN患者重要的死亡原因。迄今为止DN的发病机制尚未完全明了，涉及了多个方面［1］，如代谢紊乱、血流动力学异常、细胞因子和遗传因素等。近年研究表明，转化生长因子β(transforming growth factor-beta，TGF-β)在DN发病机制中起重要作用［2］，这为本研究提供了重要的理论依据。芪丹益肾降糖丸是治疗DN的临床经验方［3］，具有益气养阴、温肾健脾、活血利水等功效。我们观察了早期糖尿病肾病患者服用芪丹益肾降糖丸治疗前后尿微量蛋白及肾功能、血脂、血清TGFβ1等的变化，旨在探讨芪丹益肾降糖丸对早期DN患者的治疗作用